Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about First-time pregnancy complications linked to increased risk of hypertension later in life
Women who experience complications such as preterm births and preeclampsia during their first pregnancy are nearly twice more likely than women without complications to develop high blood pressure later in life — some as quickly as three years later, according to a new study of more than 4,000 women.

The study was published today in the Journal of the American Heart Association. It was funded largely by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
- Read more about NIH forms new collaborative influenza vaccine research network
National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has initiated the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, a new network of research centers that will work together in a coordinated, multidisciplinary effort to develop more durable, broadly protective and longer-lasting influenza vaccines. NIAID will provide up to approximately $51 million in total first-year funding for the program, which is designed to support the CIVICs program centers over seven years.
- Read more about Torrent Pharma expanding its recall for Losartan Potassium Tablets
Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity while testing the below finished product batches manufactured utilizing active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited using the old Route of Synthesis.
- Read more about FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
The U.S. Food and Drug Administration approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids (steroid hormones).

It is the first approved treatment for children with these rare vasculitis diseases, in which a patient’s small blood vessels become inflamed, reducing the amount of blood that can flow through them. This can cause serious problems and damage to organs, most notably the lungs and the kidneys. It also can impact the sinuses and skin.
- Read more about Second Ebola vaccine to complement “ring vaccination” given green light in DRC
The health authorities in the Democratic Republic of the Congo (DRC) have announced plans to introduce a second experimental Ebola vaccine, manufactured by Johnson & Johnson, from mid- October.

This vaccine, which is given as a 2-dose course, 56 days apart, will be provided under approved protocols to targeted at-risk populations in areas that do not have active Ebola transmission as an additional tool to extend protection against the virus.
- Read more about Multilateral agencies launch a joint plan to boost global health goals
United Nations General Assembly, 12 multilateral agencies launched a joint plan to better support countries over the next 10 years to accelerate progress towards the health-related Sustainable Development Goals (SDGs).

Developed over 18 months, Stronger Collaboration, Better Health: Global Action Plan for Healthy Lives and Well-being for All outlines how a dozen multilateral health, development and humanitarian agencies will collaborate to be more efficient and provide more streamlined support to countries to deliver universal health coverage and achieve the health-related SDG targets.
- Read more about Glenmark receives approval from Russian Ministry of Healthcare to market Montlezir film-coated tablets
Glenmark Pharmaceuticals Ltd., a research-led, integrated global pharmaceutical company, today announced that it has received approval from the Ministry of Healthcare, Russia to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film-coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age. Montlezir is expected to be available in the Russian market in Q3 FY 2019-20.
- Read more about DCGI took measures on Ranitidine contamination to ensure patient safety
DCGI asked manufacturers of Ranitidine API & formulations to verify their products and take appropriate measures to ensure patient safety after news of ranitidine contamination came in picture.
- Read more about FDA approves treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis that shortens duration of treatment to eight weeks
The U.S. Food and Drug Administration expanded the approval of Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ages 12 years and older or weighing at least 99 pounds who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis and have not been previously treated for HCV (treatment-naïve). Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis. Standard treatment length for patients with compensated cirrhosis was previously 12 weeks or more.
(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Change of name of liposomal medicines at high risk of medication errors: EMA
Marketing authorisation holders of medicines containing liposomal drug delivery systems are requested to submit a variation to change the names of liposomal medicines, but only if there is a high risk of medication errors which would raise concerns regarding the safe use of the medicinal product.